Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
GlobeNewswire - 2024-04-10T14:10:07.731Z

Findings underscore the liver safety of AD04 as compared to placebo in the prior Phase 3 clinical trial... Read this story

Related Articles

Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
by Yahoo Finance
EXCLUSIVE: Adial Pharmaceuticals' Potential Treatment For Alcohol Use Disorder Shows Encouraging Safety,
by Benzinga
Real-World Data on Mavacamten Builds on Clinical, Safety Profile
by Pharmacy Times

Latest in News

Higher Ground: Community Science Unifies Us Around Climate Change
by WNYC
Magnificent Seven ETF (MAGS) Hits New 52-Week High
by Zacks Investment Research
Ravindra Jadeja turns Superman to pull off a one-handed blinder, leaves skipper Ruturaj Gaikwad in total disbelief. Watch
by Times of India

Nate Diaz targeted in new Rodney Petersen lawsuit for New Orleans street brawl, Diaz rep responds
by MMA Fighting
In photos: Moments from Washington for the week of April 16, 2024 - All Photos
by UPI.com
Colorado Rockies' Recent United Airlines Charter Flight Under Federal Investigation
by Sports Illustrated

More from GlobeNewswire | Nasdaq:ADIL Adial Pharmaceuticals Inc Pharmaceutical industry Alcoholism Safety Clinical trial